{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:32:23Z","timestamp":1790706743607,"version":"4.1.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"27","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2217\/fon-2022-0596","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T08:32:34Z","timestamp":1659601954000},"page":"2999-3009","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia"],"prefix":"10.1080","volume":"18","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"Department of Leukemia,MD Anderson Cancer Center,\rHouston,\rTX 77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology,Juntendo University School of Medicine,\rTokyo,\r113-8421,\rJapan"},{"name":"PharmaEssentia Japan KK,\rTokyo,\r107-0051,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Medicine,School of Clinical Medicine,the University of Hong Kong,\rHong Kong SAR,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital,Zhejiang University School of Medicine,\rHangzhou,\r310006,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology,Catholic Hematology Hospital,Seoul St. Mary\u2019s Hospital,College of Medicine,The Catholic University of Korea,\rSeoul,\rTX,\r06591,\rKorea, Republic of (South) Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Division of Hematology,National Taiwan University Hospital,\rTaipei,\r100,\rTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sato","sequence":"additional","affiliation":[{"name":"PharmaEssentia Japan KK,\rTokyo,\r107-0051,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corp.,\rTaipei,\r115,\rTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Urbanski","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corporation,\rBurlington,\rMA,\r01803"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichung","family":"Shih","sequence":"additional","affiliation":[{"name":"Biostatistics School of Public Health, Rutgers,The State University of New Jersey,\rNew Brunswick,\rNJ 08901,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[{"name":"PharmaEssentia U.S.A. Corp.,\rBurlington,\rMA 01803,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corporation,\rBurlington,\rMA,\r01803"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A","family":"Mesa","sequence":"additional","affiliation":[{"name":"UT Health San Antonio Cancer Center,\rSan Antonio,\rTX 78229,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7595"},{"key":"e_1_3_2_4_1","unstructured":"NCCN . National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: myeloproliferative neoplasms. version 1.2022 (2022). www.nccn.org"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100714"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715580068"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26008"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08430.x"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.893310"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071096"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.601"},{"key":"e_1_3_2_13_1","unstructured":"Genentech Inc . PEGASYS (peginterferon alfa-2a) [package insert]. U.S. Food and Drug Administration website. (2022). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103964s5204lbl.pdf"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000428"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15176"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071954"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12613"},{"issue":"2","key":"e_1_3_2_20_1","first-page":"425","article-title":"PEG-interferon conjugates: effects of length and structure of linker","volume":"26","author":"Sabar MF","year":"2013","unstructured":"Sabar MF , KausarS, ZafarAU. PEG-interferon conjugates: effects of length and structure of linker. Pak. J. Pharm. Sci.26(2), 425\u2013430 (2013).","journal-title":"Pak. J. Pharm. Sci."},{"key":"e_1_3_2_21_1","unstructured":"PharmaEssentia USA Corporation . BESREMi (ropeginterferon alfa-2b) Prescribing Information. Burlington MA USA (2021)."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118584"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92881-4"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90005-0"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.09.018"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12613"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10098-y"},{"key":"e_1_3_2_30_1","unstructured":"Data on File . PharmaEssentia USA."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1458"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-010-0078-7"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404743"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26332"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04717-3"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92625-6"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04251.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07679.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08118.x"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb01790.x"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb00309.x"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21086"},{"issue":"10","key":"e_1_3_2_45_1","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study","volume":"90","author":"Langer C","year":"2005","unstructured":"Langer C , LengfelderE, ThieleJet al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica90(10), 1333\u20131338 (2005).","journal-title":"Haematologica"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23018"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442012"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659060"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.479.479"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.01.006"},{"key":"e_1_3_2_53_1","unstructured":"Bristol-Myers Squibb Company . HYDREA (hydroxyurea) prescribing information (2016)."},{"key":"e_1_3_2_54_1","unstructured":"Bristol-Myers Squibb Pharmaceuticals uc . HYDREA (hydroxyurea) summary of product characteristics. Dublin Ireland (2021)."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:46Z","timestamp":1719125026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":52,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2217\/fon-2022-0596"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0596","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}